Literature DB >> 15841306

Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease.

Claudia Dellas1, David J Loskutoff.   

Abstract

Although plasminogen activator inhibitor 1 (PAI-1) is one of the primary regulators of the fibrinolytic system, it also has dramatic effects on cell adhesion, detachment and migration. PAI-1 also differs from other serine protease inhibitors (serpins) in that it is a trace protein in plasma, it has a short half-life in vivo, its synthesis is highly regulated, and it binds to the adhesive glycoprotein vitronectin (VN) with high affinity and specificity. These unique and diverse properties of PAI-1 probably account for the many observations in the literature that correlate abnormalities in PAI-1 gene expression with a variety of pathological conditions. In this review, we discuss the discovery, origin, properties and regulation of PAI-1, and then speculate about its potential role in vascular disease, fibrosis, obesity and the metabolic syndrome, and cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15841306     DOI: 10.1160/TH05-01-0033

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  105 in total

1.  Synergistic and multidimensional regulation of plasminogen activator inhibitor type 1 expression by transforming growth factor type β and epidermal growth factor.

Authors:  Xiaoling Song; Frederic W Thalacker; Marit Nilsen-Hamilton
Journal:  J Biol Chem       Date:  2012-02-10       Impact factor: 5.157

2.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.

Authors:  Lawrence C Thompson; Sumit Goswami; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

Review 3.  Adipocyte-derived hormones, cytokines, and mediators.

Authors:  Cristina M Rondinone
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 4.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

5.  Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.

Authors:  Mehmet Agirbasli; Mesut Eren; Songul Yasar; Kenan Delil; Fatih Goktay; Ebru Toksoy Oner; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

Review 6.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

7.  Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.

Authors:  R-M Liu; T van Groen; A Katre; D Cao; I Kadisha; C Ballinger; L Wang; S L Carroll; L Li
Journal:  Neurobiol Aging       Date:  2009-07-14       Impact factor: 4.673

8.  Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4.

Authors:  Chang Hyun Byon; Robert W Hardy; Changchun Ren; Selvarangan Ponnazhagan; Danny R Welch; Jay M McDonald; Yabing Chen
Journal:  Lab Invest       Date:  2009-09-14       Impact factor: 5.662

9.  Shotgun proteomics implicates extracellular matrix proteins and protease systems in neuronal development induced by astrocyte cholinergic stimulation.

Authors:  Nadia H Moore; Lucio G Costa; Scott A Shaffer; David R Goodlett; Marina Guizzetti
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

Review 10.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.